RxDoctor Payments Data

Paolo Tarantino

Medical Oncology · Boston, MANPI 1619747359

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $70,726 of the $86,914 with a category attached, or 81.4%. 9 manufacturers reported payments, led by Astrazeneca UK Limited at 47.1% of the total.

$86,914in general payments, 2019–2025

Across 138 payments — averaging $629.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$41K
  • AstraZeneca$26K
  • Gilead$9K
  • F. Hoffmann-la Roche AG$3K
  • Stemline Therapeutics Inc.$2K
  • Sanofi$2K
  • plus $3K from 3 others
$353,789in research payments, 2019–2025

Across 7 payments — averaging $50,541 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$342K
  • Novartis$12K

What the payments were for

  • Consulting fees$70,72681%
  • Speaking & faculty fees$1,8622%
  • Travel & lodging$8,2389%
  • Food & beverage$6,0887%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,914 in reported general payments places this provider in the 80th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Other medical oncology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →